Xiaoyan S. Kang
Jinan, 250131, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 45 publications
A first-in-class bifunctional antibody targeting CD20 and CD37 remodels the immune microenvironment in relapsed or refractory B-cell malignancies.
Journal: Journal of hematology & oncology
Published: December 26, 2025
A first-in-class bifunctional antibody targeting CD20 and CD37 remodels the immune microenvironment in relapsed or refractory B-cell malignancies.
Journal: Journal of hematology & oncology
Published: December 26, 2025
Effect of obstructive sleep apnea-hypopnea syndrome on myocardial mechanics in obese patients.
Journal: Frontiers in cardiovascular medicine
Published: July 24, 2025
Iparomlimab and tuvonralimab in previously treated patients with cervical cancer.
Journal: Cell reports. Medicine
Published: May 29, 2025
Heterogeneous cellular responses to hyperthermia support combined intraperitoneal hyperthermic immunotherapy for ovarian cancer mouse models.
Journal: Science translational medicine
Published: March 12, 2025
Iparomlimab and tuvonralimab (QL1706) plus chemotherapy and bevacizumab for EGFR-mutant patients with advanced non-small cell lung cancer after failure of EGFR-tyrosine kinase inhibitors: updated results from cohort 5 in the DUBHE-L-201 study.
Journal: Journal of hematology & oncology
Published: March 11, 2025
Translational Model-Informed Dose Selection for Iruplinalkib, a Selective Oral ALK/ROS1 Tyrosine Kinase Inhibitor.
Journal: Clinical and translational science
Published: February 12, 2025
Comparison of efficacy and safety of a proposed biosimilar QL1206 with reference denosumab in patients with bone metastasis from breast cancer: A subgroup analysis of a randomized, double-blinded phase III study.
Journal: Chinese journal of cancer research = Chung-kuo yen cheng yen chiu
Published: December 25, 2024
Updated efficacy and predictive biomarkers of QL1706, a bifunctional PD-1/CTLA-4 dual blocker in advanced solid tumors-A phase 1/1b study.
Journal: Cell reports. Medicine
Published: December 18, 2024
Plasma exosomes from patients with coronary artery disease promote atherosclerosis via impairing vascular endothelial junctions.
Journal: Scientific reports
Published: October 02, 2024
Iparomlimab (QL1604) in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) unresectable or metastatic solid tumors: a pivotal, single-arm, multicenter, phase II trial.
Journal: Journal of hematology & oncology
Published: August 05, 2024
Population pharmacokinetics of iruplinalkib in healthy volunteers and patients with solid tumors.
Journal: Clinical and translational science
Published: July 18, 2024
Last Updated: 09/26/2026